Risk factor
Limited trading liquidity
Profitability factor
Slightly undervalued vs peers
About
Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of f
Target Price
The average target price of SBS.DE is 26.3 and suggests 6.22% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat